Dexmedetomidine

Dexmedetomidine

Form: Intravenous (IV) Infusion/Injection

Strength: 100 mcg/mL

Reference Brands: Precedex(US); Dexdor(EU)

Category: Critical Care

Dexmedetomidine is a highly selective alpha-2 adrenergic agonist used for sedation in ICU and surgical settings without causing respiratory depression. Available as a 100 mcg/mL concentrate in 2 mL and 4 mL vials, and as ready-to-use infusions (4 mcg/mL in 50 mL and 100 mL), it ensures flexible dosing and efficient workflow. In the US, Precedex by Pfizer and generic alternatives are widely used. The EU features Dexdor (Orion), Accord, and B. Braun formulations. Dexmedetomidine is a critical care drug frequently procured via pharma B2B platforms for operating rooms, ICUs, and procedural sedation in institutional healthcare settings.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (IV)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.